This series on “Carcinoma of Pancreas” is edited by Dr. Eric C. H. Lai from Hong Kong, China
Eric C. H. Lai
Dr. Lai is currently a General Surgeon in Hong Kong SAR, China. He is the Guest Editor, Chinese Clinical Oncology. Dr. Lai’s clinical research has focused on liver, bile duct, and gallbladder cancers, and minimally invasive therapy for Hepato-Pancreato-Biliary diseases. He has published more than 170 peer-reviewed publications and more than 20 book chapters. Outside of the hospital, he also currently serves as editorial board members of several peer-reviewed journals.
Series outline
- Introductory preface for the special series
- Genetic profile and molecular bases of carcinogenesis of pancreatic ductal adenocarcinoma
- Biomarkers in early detection of pancreatic ductal adenocarcinoma
- Surgical management of pancreatic cancer
- Minimally invasive surgery of pancreaticoduodenectomy for pancreatic cancer
- Minimally invasive surgery of distal pancreatectomy for pancreatic cancer
- Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic ductal adenocarcinoma
- Drug therapy for pancreatic ductal adenocarcinoma
- Stereotactic body radiotherapy in the management of pancreatic adenocarcinoma
Disclosure:
The special series “Carcinoma of Pancreas” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship. Eric C. H. Lai is serving as the unpaid Guest Editor for the special series.